Kornimate/medical-research-clean huggingface dataset:
lipoic acid for progressive multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: the purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.

this two-year study will determine if daily oral intake of lipoic acid will prove superior to placebo in reducing injury to the brain and maintaining mobility in progressive ms. mobility will be assessed with the timed 25-foot walk test and 2-minute timed walk test as well as fall counts. neuroprotection will be measured by the extent of brain volume loss seen on mri.

Eligibility criteria:
inclusion criteria: * diagnosis of progressive ms as defined by the study * able to give informed consent and to adhere to study procedures. * expanded disability status scale (edss) 3.0 - 6.5: ambulatory for at least 20 meters without rest and use of bilateral aids (canes, crutches, walker) or better. exclusion criteria: * a self-reported medical or neurological problem other than ms that is a cause of progressive or fluctuating gait dysfunction * unable to undergo mri * unable to follow directions in english as standardized scales are not all validated in other languages. * current major disease or disorder other than ms (e.g., cancer, renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may interfere with study procedures. note: stable abnormal laboratory values of no more than grade 1 determined to not be of clinical significance to the primary treating physician for that condition may be permitted per local site investigator discretion. * pregnant or breast-feeding. * insulin-dependent diabetes or diabetes not controlled on oral diabetes medications. * scheduled (every 3 months or more frequently) iv or oral steroids in the year prior to enrolment. * iv or oral steroids in the 60 days prior to enrolment. * use of la in the prior 2 years exceeding the equivalent of 1200mg daily for 3 months. * participation in the pilot la in spms trial.

Keywords: multiple sclerosis magnetic resonance imaging gait neuroprotective agents thioctic acid alpha-lipoic acid mobility chronic progressive multiple sclerosis
a study of shr-1210 in combination with bp102 in subjects with non-squamous nsclc

Conditions: Lung Neoplasms

Summary: shr-1210 is a humanized anti-pd1 igg4 monoclonal antibody. this is a phase ii, multicenter, open-label study designed to evaluate the safety and efficacy of shr-1210 with bp102 in subjects who are chemotherapy naive and have stage iiib\~iv non-squamous nsclc. the primary end points are orr and pfs. in this study, subjects will receive shr-1210 combined with bp102 until progression or unacceptable toxicity (shr-1210 or bp102 for a maximum of 2 years).


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of ≤ 1; * subjects who are chemotherapy naive and have stage iiib-iv non-squamous nsclc; * gene diagnostic tests must show that subjects are with wild type of egfr, alk and ros1; * known pd-l1 status as determined by immunohistochemistry assay performed on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening; * no prior systemic treatment; * adequate hematologic and end organ function; * female participants of childbearing potential must have a negative serum pregnancy test within -7 days of randomization and must be willing to use very efficient barrier methods of contraception or a barrier method plus a hormonal method starting with the screening visit through 6 months after the last dose male participants with a female partner(s) of child-bearing potential must be willing to use very efficient barrier methods of contraception from screening through 6 months after the last dose. exclusion criteria: * significant cardiovascular disease; * prior treatment with immune checkpoint blockade therapies, anti-programmed death-1, and anti-pd-l1 therapeutic antibodies; * history of autoimmune disease; * malignancies other than nsclc within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome; * severe infection within 4 weeks prior to randomization; * administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live attenuated vaccine will be required during the study; * major surgical procedure within 4 weeks prior to randomization; * history of hemoptysis within 12 weeks prior to randomization; * inadequately controlled hypertension; * evidence of bleeding diathesis or coagulopathy; * prior allogeneic bone marrow transplantation or solid organ transplant; * positive test for hiv, and patients with active hepatitis b or hepatitis c.
zhaoqing myopia study

Conditions: Myopia

Summary: myopia is a common cause of vision loss, being particularly prevalent in children in east and southeast asia. the investigators will assess prevalence and incidence of myopia, identify digital biomarkers associated with myopia, and validate algorithms for the detection and/or predition of myopia and other ocular abnormalities in school-aged children in both urban and rural settings in southern china.

myopia is a common cause of vision loss, being particularly prevalent in east and southeast asia. it is still not entirely clear whether and how visual experience in an urban environment with less outdoor exposure could have an impact on the development and progression of myopia. zhaoqing has a relatively stable population of 4,084,600, which are representative of the chinese population in term of demographic and socioeconomic characteristics. therefore, the investigators will conduct a longitudinal cohort study in both urban and rural settings to examine prevalence and incidence of myopia, identify digital biomarkers associated with myopia, and validate algorithms for the detection and/or predition of incidence and progression of myopia and other ocular abnormalities in school-aged children in zhaoqing.

Eligibility criteria:
inclusion criteria: * all first-grade students from 10 primary schools in urban counties, and from 10 primary schools in rural counties, zhaoqing city. exclusion criteria: * no.
continuous pre-uterine wound infiltration versus intrathecal morphine for postoperative analgesia after cesarean section

Conditions: Postoperative Pain

Summary: the cesarean section is considered as a painful surgery during the post operative period. mothers may need to move immediately after the surgery to take care of their babies. this may increase the risk of major pain and chronic pain. thus, excellent postoperative analgesia is required so that mothers do not experience pain in caring for their baby. currently, several techniques have been developed to manage postoperative pain related to c-section scar such as intrathecal morphine during spinal anesthesia or continuous pre-peritoneal wound infiltration. the comparison between anesthetic techniques has never been performed and it is still not know if the combination of intrathecal morphine plus continuous pre-peritoneal wound infiltration provide a synergistic or additional effect on pain relief.

the aim of this study is to compare the efficacy of continuous wound infiltration versus intrathecal morphine for postoperative analgesia after scheduled cesarean section. the primary endpoint is morphine consumption during the first 48 postoperative hours.

Eligibility criteria:
inclusion criteria: * elective cesarean section * spinal anesthesia * singleton * asa ( physical status score) 1 to 3 exclusion criteria: * age \<18yrs * bmi ≥ 45 kg/m2 or weight \< 45 kg * refusal to consent * urgent cesarean section * allergy to a medication used in the protocol * impaired hemostasis ou current infection * contra indication or failure of spinal anesthesia

Keywords: cesarean section spinal anesthesia continuous wound infiltration intrathecal morphine oral morphine
efficacy of the use of dry needling in conventional non-invasive treatment of acute and subacute whiplash

Conditions: Whiplash Injuries

Summary: introduction: whiplash is an injury produced by an acceleration-deceleration mechanism that transmits energy to the cervical spine. according to the bibliography, the conservative treatment (motor control exercises and manual therapy) has shown benefits in approaching this lesion, but its efficacy is limited. dry needling has already shown its usefulness in different musculoskeletal pathologies, however, its efficacy is unknown when it is included in conservative treatment. objectives: the objective of this study is to assess the effects of the incorporation of dry needling in the conventional treatment with manual therapy and motor control exercises, compared to the conventional non-invasive treatment in patients with acute or subacute whiplash. hypothesis: the inclusion of dry needling in conventional non-invasive treatment is more effective than conventional non-invasive treatment in patients with acute or subacute whiplash. methods: a randomized clinical trial will be conducted in which the subjects of study will be assigned to two groups, a control group (conventional treatment) and an experimental group (conventional treatment and dry needling).


Eligibility criteria:
inclusion criteria: * medical diagnosis of whiplash grade i-ii in the qtf * neck pain * whiplash in acute or subacute phase exclusion criteria: * pregnancy * belonephobia * cervical fractures-dislocations or neurological deficit secondaries to accident * previous surgery of the cervical spine * circulatory disease, respiratory disease, neurological disease, rheumatologic disease and mental illness * athletes

Keywords: dry needling manual therapy motor control whiplash
sedation and analgesia using pfk versus general anesthesia in urological procedures

Conditions: Anesthesia; Urologic Diseases

Summary: anesthesia in urological surgeries might constitute a great challenge to anesthesiologists. especially that a great proportion of these patients are elderly with a lot of comorbidities. this put these patients at the risk of developing medical adverse events after being anesthetized by general anesthesia. the aim of this study is to compare between intravenous sedation with analgesia versus general anesthesia in patients undergoing urological surgical procedures.

anesthesia in urological surgeries might constitute a great challenge to anesthesiologists. especially that a great proportion of these patients are elderly with a lot of comorbidities. this put these patients at the risk of developing medical adverse events after being anesthetized by general anesthesia. the aim of this study is to compare between intravenous sedation with analgesia versus general anesthesia in patients undergoing urological surgical procedures. the first group which underwent general anesthesia, was anesthetized using fentanyl (2 mcg per kg) and propofol (1-2 mg per kg). laryngeal mask airway was then inserted. the second group underwent intravenous sedation and analgesia by using a mixture of fentanyl, propofol and ketamine (pfk mixture). the mixture consists of 100 mcg fentanyl, 100 mg propofol, 100 mg of ketamine. in addition, 40 mg of lidocaine were added, this aimed to reduce the pain on injection caused by propofol. moreover, 4 ml of water of injection were added to the mixture. this resulted in a mixture of 5 mcg/ml of fentanyl, 5 mg/ml of propofol, and 5 mg/ml of ketamine. by this, each ml of the mixture contained 10 mg (ketamine and propofol) + 5 mcg fentanyl. each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. no laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on support of 3 l/min o2.

Eligibility criteria:
inclusion criteria: * patients above the age of 30 years * patients who were admitted for minor urological surgeries under the care of urology team. minor urological procedures, included cystoscopy, trans-urethral resection of tumor (turt), uretroscopy, double j insertion, and double j removal. exclusion criteria: * patient refusal. * urgent and emergency cases, which were not elective procedures. * surgeries that were expected to take a long duration (more than 1.5 hour).

Keywords: general anesthesia sedation propofol fentanyl ketamine hypotension
the effects of resistance exercises in glycemic control of women with gestational diabetes

Conditions: Gestational Diabetes

Summary: the object of this study is to evaluate patients with a diagnosis of gd who are included in a program of re carried out with rubber tubes, comparing the frequency of women who will use insulin in the group who will participate in the program with the group that won't do the exercises, and to verify the impact of the program on the adequacy of capillary glycemic control of the pregnant women.


Eligibility criteria:
inclusion criteria: * gestational diabetes diagnosis * sedentary * nonsmokers * age between 18 and 45 years old * pre-pregnancy bmi less than 35, without limiting physical factor for conducting exercises * with single pregnancy without fetal malformation:gestational age between 24 and 34 weeks, which have no other condition that contraindicate the conduct of exercises, with no risk factors for preterm delivery and who consent to participate in the study exclusion criteria: * patients who develop further clinical or obstetric complications that contraindicate the conducting exercises during pregnancy * patients who start any form of physical activity after being randomized to the control group * patients who start another form of physical activity than the resistance exercises after being randomized to the intervention group * patients who were to use another product than insulin as a form of glycemic control * patients to abandon the study

Keywords: gestational diabetes resistance exercise pregnancy insulin
impacts of the covid-19 epidemic and associated lockdown measures on the management, health and behaviors of cystic fibrosis patients during the 2020 epidemic

Conditions: Cystic Fibrosis in Children; Cystic Fibrosis

Summary: impacts of the covid-19 epidemic and associated lockdown measures on the management, health and behaviors of cystic fibrosis patients during the 2020 epidemic

the containment of the population in france is a health measure implemented in response to sars-cov-2 (covid-19) infection. for cystic fibrosis, as for many chronic diseases, this disruption is twofold. on the one hand, it affects daily life due to the closure of schools and the introduction of national lockdown, but also the hospital, which has profoundly changed its procedures, which are almost completely focused on the care of patients with covid-19. this forced transformation was at the expense of its usual role including the management of chronic diseases such as cystic fibrosis. it has an impact on patients' consultations cancelled, rescheduled or replaced by teleconsultations, hospitalisations whether scheduled or during acute exacerbations which are more complicated to organise. access to treatments is also more difficult (physiotherapy), which can affect compliance. confinement also profoundly changes the lives of our patients. it changes the way individuals can apprehend their disease and its integration into their everyday life, studies or professional projects. finally, it is the confrontation with a potentially fatal infection that reminds us of the risks and consequences of a potentially severe chronic disease.

Eligibility criteria:
inclusion criteria: * patient with cystic fibrosis (southern chlorine \> 60 meq/l and/or presence of 2 pathogenic mutations on the cftr gene) * supported in a french crcm (cystic fibrosis resource and competence center) * affiliated to a social security scheme * non-opposition for participation in the protocol exclusion criteria: * minor patient under 14 years of age * computer equipment or internet connection defect

Keywords: lockdown covid-19 epidemic questionnaire interview
efficacy of virtual reality on balance in children with ataxic cerebral palsy randomized controlled trail

Conditions: Ataxic Cerebral Palsy

Summary: ataxic cp is one type of cerebral palsy. children with ataxic cerebral palsy have trouble with balance and coordination. they may walk with their legs farther apart than other kids and have a hard time with activities that use small hand movements, like writing. some also have trouble with depth perception this means being able to accurately judge how close or far away something is


Eligibility criteria:
inclusion criteria: * ataxic cerebral palsy aged 9-14 years exclusion criteria: * any musculoskeletal conditions that affect balance previous surgeries that affecting balance
magnesium supplementation for the prevention of supraventricular arrhythmias

Conditions: Premature Atrial Contraction

Summary: the primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).

to evaluate the primary objective, the investigator will conduct a double-blind randomized trial assigning participants to receive 400 mg of oral magnesium in the form of magnesium citrate once daily or placebo. the investigators will recruit 60 individuals 55 years of age and older without a prior history of cardiovascular disease. at baseline, participants will undergo a basic examination, answer questionnaires and provide a blood sample to determine circulating magnesium levels. participants will then wear an fda-approved heart rhythm monitor (zio ® xt patch) for 2 weeks. at the end of 2 weeks they will begin taking their assigned treatment (magnesium or placebo), and will continue doing so for a total of 12 weeks (through study week 14). after 10 weeks of taking the supplement or placebo (study week 12), they will have a final study visit in which the participants will provide another blood sample for assessment of circulating magnesium, and will be asked to wear the heart rhythm monitor for another 2 weeks (through study week 14). the primary endpoint will be the change in burden of premature atrial contractions (pacs), measured in episodes per day, between baseline and final follow-up visit. a secondary outcome will be the change in circulating magnesium between both exams.

Eligibility criteria:
inclusion criteria: * age 55 and older * ability to speak english * availability to attend baseline and follow-up visit approximately 12 weeks after baseline exclusion criteria: * prior history of heart disease (coronary heart disease, heart failure, atrial fibrillation), stroke, severe renal disease * use of type i and iii antiarrhythmics or digoxin * current use of magnesium supplements * any prior history of allergy or intolerance to magnesium * prior history of inflammatory bowel disease or any severe gastrointestinal disorder

Keywords: magnesium supplementation magnesium dietary supplement arrhythmia
omitting sentinel node procedure in breast cancer patients undergoing breast conserving therapy

Conditions: Breast Neoplasms

Summary: study aim to decrease the number of breast cancer patients receiving over treatment of the axilla, in order to positively influence the axillary morbidity rate and quality of life. primary objective to determine whether omitting the sentinel lymph node procedure is not inferior to the current axillary staging regimen in clinically node negative breast cancer patients undergoing breast conserving therapy, in terms of regional recurrence rate. hypothesis the sentinel lymph node procedure can be safely omitted in clinically node negative breast cancer patients undergoing breast conserving therapy. this will lead to a decreased axillary morbidity rate, with a non-inferior regional recurrence-, distant-disease free- and overall survival rates.


Eligibility criteria:
inclusion criteria: * female * aged 18 years or older * pathologically confirmed invasive breast carcinoma * a clinical t1-2 tumor * will be treated with lumpectomy and whole breast radiotherapy * clinically node negative status: no signs of axillary lymph node metastases at physical examination and preoperative axillary ultrasound (or negative cyto-/histopathology) * written informed consent exclusion criteria: * clinically node positive pre-operative * bilateral breast cancer * evidence of metastatic disease * history of invasive breast cancer * previous treatment of the axilla with surgery or radiotherapy (except surgery for hidradenitis suppurativa or for other superficially located skin lesions, such as naevi) * pregnant or nursing * other prior malignancies within the past 5 years (except successfully treated basal cell and squamous cell skin cancer, carcinoma in situ of the cervix or carcinoma in situ of the ipsilateral or contralateral breast) or unsuccessfully treated malignancies \> 5 years before randomization * unable or unwilling to give informed consent
treatment of latent tuberculosis infection with isoniazid

Conditions: Tuberculosis

Summary: the purpose of this study is to study the effect that treatment of dormant tuberculosis infection has on the immunological system. we expect to observe an impact over the production of cytokines by peripheral white blood cells which may be useful to know if treatment has been effective.

as part of on-going studies conducted in the orizaba health jurisdiction in southeastern mexico, household contacts of pulmonary tb patients who recently converted their tuberculin test and tst+ve contacts from randomly selected control households with no history of tb within the last 2 years (remote contacts) will be enrolled. we assume that these individuals are infected with mycobacterium tuberculosis. additional confidence that all subjects enrolled are latently infected will come from elispot analysis of the response to esat-6 and cfp-10. we propose to administer inh to 100 tst+ve recent and 100 tst+ve remote contacts for 6 months. to control for spontaneous fluctuations of biomarker levels, we propose to defer therapy by 3 months to half the subjects in each group. thus, four groups will be defined: a. recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment. b. recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment. c. remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment. d. remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment. all contacts will undergo clinical evaluation at enrolment and review. the development of active tb will trigger withdrawal and full treatment. fortnightly clinical review of group b during the deferred phase will be undertaken. elispot analysis will be performed on all subjects at 0, 1, 4, 13, 26 and 40 weeks in groups a and c, and at 0, 13, 14, 17, 26, 40 and 54 weeks in groups b and d. a subset of 10 patients per group will be sampled for expression analysis at 0, 4, 26 and 40 weeks (groups a and c) and at 0, 13, 17 and 40 weeks in groups b and d (160 hybridizations in total).

Eligibility criteria:
inclusion criteria: * informed consent * age 10-45 * either sex * resident in study area * documented tst+ve (\>10mm, mantoux method, 2tu, ppd statens serum institute) * normal chest radiograph * hiv negative test exclusion criteria: * active tuberculosis * previous diagnosis of tuberculosis * treatment for active or latent tuberculosis * contact with tb patients harboring mdr or inh resistant isolates of mtb * diseases or therapies associated with immunosuppression * diabetes mellitus * abnormal liver enzyme levels. * hb below 8gr/dl * pregnancy (ascertained by urinary β-hcg) * allergy or intolerance to isoniazid * peripheral neuropathy * ingestion of drugs interacting with isoniazid

Keywords: latent tuberculosis biomarkers isoniazid elispot ppd positive individuals